Literature DB >> 27501371

Bioresorbable scaffold-the holy grail of percutaneous coronary intervention: fact or myth?

Kevin Liou1, Nigel Jepson1.   

Abstract

Year:  2016        PMID： 27501371      PMCID： PMC4958786          DOI： 10.21037/jtd.2016.05.27

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  18 in total

1.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.

Authors:  Gregg W Stone; Ali Rizvi; William Newman; Kourosh Mastali; John C Wang; Ronald Caputo; Julie Doostzadeh; Sherry Cao; Charles A Simonton; Krishnankutty Sudhir; Alexandra J Lansky; Donald E Cutlip; Dean J Kereiakes
Journal:  N Engl J Med       Date:  2010-05-06       Impact factor: 91.245

2.  Emergency stenting for acute occlusion after coronary balloon angioplasty.

Authors:  U Sigwart; P Urban; S Golf; U Kaufmann; C Imbert; A Fischer; L Kappenberger
Journal:  Circulation       Date:  1988-11       Impact factor: 29.690

3.  Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty.

Authors:  A R Grüntzig; A Senning; W E Siegenthaler
Journal:  N Engl J Med       Date:  1979-07-12       Impact factor: 91.245

4.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

Authors:  D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

5.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

6.  Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice).

Authors:  Pieter C Smits; Georgios J Vlachojannis; Eugene Patrick McFadden; Kees-Jan Royaards; Jochem Wassing; Kaiyum Sheik Joesoef; Carlos van Mieghem; Martin van de Ent
Journal:  JACC Cardiovasc Interv       Date:  2015-07-22       Impact factor: 11.195

7.  Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers.

Authors:  Daniel Robaei; Liam Back; Sze-Yuan Ooi; Mark Pitney; Nigel Jepson
Journal:  J Invasive Cardiol       Date:  2015-11-15       Impact factor: 2.022

8.  Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

Authors:  Stephen G Ellis; Dean J Kereiakes; D Christopher Metzger; Ronald P Caputo; David G Rizik; Paul S Teirstein; Marc R Litt; Annapoorna Kini; Ameer Kabour; Steven O Marx; Jeffrey J Popma; Robert McGreevy; Zhen Zhang; Charles Simonton; Gregg W Stone
Journal:  N Engl J Med       Date:  2015-10-12       Impact factor: 91.245

9.  Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI).

Authors:  Issam D Moussa; Lloyd W Klein; Binita Shah; Roxana Mehran; Michael J Mack; Emmanouil S Brilakis; John P Reilly; Gilbert Zoghbi; Elizabeth Holper; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2013-10-22       Impact factor: 24.094

Review 10.  Bioresorbable scaffolds: rationale, current status, challenges, and future.

Authors:  Javaid Iqbal; Yoshinobu Onuma; John Ormiston; Alexandre Abizaid; Ron Waksman; Patrick Serruys
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.